As shown in Figure 2C and 2D, phosphorylations of mTOR, FAK and ERK1/2 were significantly decreased in the groups treated with NIR-PTT (43.99±4.94%, 36.54±1.37% and 50.97±2.62%, respectively), anti-EGFR (43.46±6.43%, 33.60±2.59% and 22.64±2.79%, respectively), anti-EGFR-GN (28.51±4.74%, 36.34±2.11% and 23.04±4.44%, respectively) and anti-EGFR-GN+NIR-PTT (8.51±1.11%, 27.67±0.87% and 6.37±1.26%, respectively) relative to control (P<0.001). This evidence concerns the gene MAPK3 and ganglioneuroma.